Citation Impact
Citing Papers
CSR reporting practices of Eurozone companies
2014 Standout
In-vitro alpha amylase inhibitory activity of the leaf extracts of Adenanthera pavonina
2016 Standout
Navigating the confluence of artificial intelligence and education for sustainable development in the era of industry 4.0: Challenges, opportunities, and ethical dimensions
2024 Standout
Carbon Risk, Carbon Risk Awareness and the Cost of Debt Financing
2016 Standout
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
2016 Standout
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics
2010
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
fMRIPrep: a robust preprocessing pipeline for functional MRI
2018 Standout
Hepatocellular carcinoma
2016 Standout
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction
2006
Bayesian Design of Proof-of-Concept Trials
2014
Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
2012
Risk factors for surgically removed fibroids in a large cohort of teachers
2008
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Sirolimus‐based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma†
2009
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic Window
2004
Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials
2016
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
2002
Osteoarthritis
2019 Standout
Voluntary environmental disclosure quality and firm value: Further evidence
2015
An architectural framework for global talent management
2015
ESG disclosure and financial performance: Moderating role of ESG investors
2022 Standout
The sustainable management vision for excellence: implications for business education
2012
Planetary Boundaries: Ecological Foundations for Corporate Sustainability
2012 Standout
Attenuating effect of seeds of Adenanthera pavonina aqueous extract in neuropathic pain in streptozotocin-induced diabetic rats: an evidence of neuroprotective effects
2012
The Impact of Better Corporate Social Responsibility Disclosure on the Cost of Equity Capital
2011
Influences on Student Intention and Behavior Toward Environmental Sustainability
2013
Implementing sustainability as the new normal: Responsible management education – From a private business school's perspective
2017 Standout
A review of archival auditing research
2014 Standout
Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials
2016
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
2002
Corporate social responsibility and access to finance
2013 Standout
Voluntary Nonfinancial Disclosure and the Cost of Equity Capital: The Initiation of Corporate Social Responsibility Reporting
2010 Standout
The relevance of environmental disclosures: Are such disclosures incrementally informative?
2013
Formation of Interorganizational Relational Behavior in Megaprojects: Perspective of the Extended Theory of Planned Behavior
2017 Standout
The role that marketing academics play in advancing sustainability education and research
2019
The color of shareholders' money: Institutional shareholders' political values and corporate environmental disclosure
2020
Greenwashing in environmental, social and governance disclosures
2020 Standout
Nonfinancial Disclosure and Analyst Forecast Accuracy: International Evidence on Corporate Social Responsibility Disclosure
2012
The effect of pro-environmental preferences on bond prices: Evidence from green bonds
2018 Standout
Epidemiology of uterine fibroids: a systematic review
2017 Standout
Environmental, Social and Governance (ESG) disclosure, competitive advantage and performance of firms in Malaysia
2021 Standout
Does Integrated Reporting Matter to the Capital Market?
2017 Standout
Natural disasters, risk salience, and corporate ESG disclosure
2021
Going Green: Market Reaction to CSR Newswire Releases
2012
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Elevating talents' experience through innovative artificial intelligence-mediated knowledge sharing: Evidence from an IT-multinational enterprise
2021 Standout
Works of Scott Marshall being referenced
'Negotiated' Transparency? Corporate Citizenship Engagement and Environmental Disclosure
2007
The Impact of Voluntary Environmental Disclosure Quality on Firm Value
2008
Voluntary Environmental Disclosure Quality and Firm Value: Further Evidence
2010
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
2002
Validating California Teachers Study Self-Reports of Recent Hospitalization: Comparison with California Hospital Discharge Data
2003
Predictors of the placebo analgesia response in randomized controlled trials of chronic pain
2015
Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT’ Study
2008
Pharmacokinetic–Pharmacodynamic Analysis of the Static Allodynia Response to Pregabalin and Sildenafil in a Rat Model of Neuropathic Pain
2010
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
2015
The End of a “Period”: Sustainability and the Questioning Attitude
2010
THE IMPACT OF VOLUNTARY ENVIRONMENTAL DISCLOSURE QUALITY ON FIRM VALUE.
2009
A Quantitative Approach for Making Go/No-Go Decisions in Drug Development
2011
The End of a "Period": Sustainability and the Questioning Attitude.
2010